Becton, Dickinson and Company BDX, more commonly known as BD, introduced BD FACSCelesta flow cytometer at the recent 2015 American Society for Cell Biology annual meeting. The solution is primarily designed to allow more insightful single cell studies and improve data quality.
The BD FACSCelesta flow cytometer is particularly intended to optimize the usage of BD Horizon Brilliant reagent portfolio. In fact, the solution along with BD Horizon Brilliant polymer dyes facilitates superior resolution of cell population, which went unnoticed previously.
Further, the system can simultaneously measure up to 14 diverse single cell characteristics and is a perfect solution for researchers looking for more fluorophore choices while using multicolor flow cytometry. The BD FACSCelesta flow cytometer is available in four configurations, which will aid the utilization of 10–12 different colors.
The new solution, which will be a part of the company’s BD cell analyzer portfolio, in turn, may drive the top-line in the coming quarters. In fiscal 2015 (ending Sep 30, 2015), revenues from the BD Life Sciences segment increased 5% on a constant currency basis to $3.82 billion.
In October this year, BD Becton launched BD FACSseq, a high-throughput cell sorter for single cell genomics applications. BD FACSseq combined with BD Precise Assays can be used for single cell gene expression analysis. The combined product will allow researchers to analyze thousands of cells in a more efficient and cost-friendly manner. BD FACSseq is currently available for research purposes. The company expects to launch the commercial version in early 2016.
According to a research report by MarketsandMarkets, the cell analysis market is expected to reach a worth of almost $23 billion by 2018, on the back of increased demand for accuracy of cell imaging and analysis systems. Hence, we believe that the introduction of new and innovative solutions will help BD gain better market traction, going forward.
Zacks Rank & Stocks to Consider
Currently, BD carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical sector are Masimo MASI, Olympus Corp OCPNY and Natus Medical BABY. All the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment